Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) Director Richard S. Levy acquired 3,550 shares of the firm’s stock in a transaction that occurred on Tuesday, August 22nd. The shares were purchased at an average price of $16.12 per share, with a total value of $57,226.00. Following the completion of the acquisition, the director now owns 3,640 shares of the company’s stock, valued at approximately $58,676.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Madrigal Pharmaceuticals Inc (NASDAQ MDGL) traded up 0.7419% on Friday, hitting $17.0153. The company had a trading volume of 1,857 shares. Madrigal Pharmaceuticals Inc has a one year low of $9.30 and a one year high of $18.24. The company’s market capitalization is $212.61 million. The stock’s 50-day moving average price is $15.76 and its 200 day moving average price is $15.71.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last announced its quarterly earnings results on Thursday, August 10th. The biopharmaceutical company reported ($0.69) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.60) by $0.09. On average, analysts expect that Madrigal Pharmaceuticals Inc will post ($2.57) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This article was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another publication, it was copied illegally and reposted in violation of US & international trademark & copyright legislation. The original version of this article can be viewed at https://www.thecerbatgem.com/2017/08/25/richard-s-levy-acquires-3550-shares-of-madrigal-pharmaceuticals-inc-mdgl-stock.html.

Separately, ValuEngine upgraded Madrigal Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, May 19th.

Large investors have recently made changes to their positions in the stock. New York State Common Retirement Fund purchased a new stake in shares of Madrigal Pharmaceuticals during the second quarter valued at $109,000. California State Teachers Retirement System purchased a new stake in shares of Madrigal Pharmaceuticals during the second quarter valued at $117,000. TIAA CREF Investment Management LLC purchased a new stake in shares of Madrigal Pharmaceuticals during the second quarter valued at $120,000. Bank of New York Mellon Corp purchased a new stake in shares of Madrigal Pharmaceuticals during the second quarter valued at $179,000. Finally, Citigroup Inc. purchased a new stake in shares of Madrigal Pharmaceuticals during the second quarter valued at $185,000. 12.58% of the stock is owned by institutional investors.

Madrigal Pharmaceuticals Company Profile

Madrigal Pharmaceuticals, Inc, formerly Synta Pharmaceuticals Corp., is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH). The Company’s lead product, MGL-3196, is a Phase II-ready once-daily, oral, liver-directed selective thyroid hormone receptor-b (THR-b) agonist for the treatment of NASH, and heterozygous and homozygous familial hypercholesterolemia (FH).

Receive News & Stock Ratings for Madrigal Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Madrigal Pharmaceuticals Inc and related stocks with our FREE daily email newsletter.